OwlTing Group Expands Visa Partnership to Unlock Seamless Debit-to-USDC On-Ramp for Mass Adoption

OwlTing Group (Nasdaq: OWLS), the operating brand of OBOOK Holdings Inc., is accelerating digital currency accessibility by integrating Visa Direct into its OwlPay platform, enabling U.S. consumers to fund USDC transactions directly with debit cards in a frictionless, familiar flow. With access to a $4.7 trillion debit card ecosystem and a regulatory footprint spanning 41 states, the company is strategically positioned to drive scalable transaction-based revenue while powering mainstream adoption of digital dollar infrastructure.

Off The Hook Yachts Launches Scalable Five-Tier Broker Model to Power Global Marketplace Expansion

Off The Hook Yachts (NYSE American: OTH) is driving the next phase of growth with a new five-tier broker expansion model designed to create a compounding, globally scalable sales network powered by its AI-driven platform. Positioned within the $57 billion U.S. marine market, the company is leveraging its rapidly growing broker base, expanded capital resources, and NextBoat AI infrastructure to unlock higher transaction velocity and long-term platform-driven revenue growth.

Horizon Aircraft Partners with Mitsubishi Subsidiary to Accelerate Cavorite X7 Development

New Horizon Aircraft (Nasdaq: HOVR) is advancing its hybrid-electric VTOL ambitions through a strategic collaboration with MHI RJ Aviation Group, leveraging deep engineering expertise to support flight test development and reduce program risk ahead of a planned 2027 test timeline. With growing demand for next-generation regional air mobility solutions, the partnership strengthens the Cavorite X7’s path toward certification and commercial scalability across multiple high-value end markets.

Greenwich LifeSciences Advances Patent Strategy to Potentially Double GP2 Market Opportunity to $10B

Greenwich LifeSciences (Nasdaq: GLSI) reported new patent claims supported by statistically significant Phase III data that could expand GP2 eligibility to non-HLA patients—effectively doubling the addressable market to approximately 88,000 patients annually across the U.S. and Europe. With potential peak revenue of up to $10 billion and patent protection extending to 2045, the company is strengthening its commercial outlook while advancing its late-stage breast cancer immunotherapy program.